Increased plasma chemoattractant in Sweet's syndrome.
The neutrophil function and plasma leukotactic activity of a patient with Sweet's syndrome and cystonodular acne were evaluated during a 2 1/2-year period. These studies demonstrated that chemotaxis was frequently slightly increased, especially during an exacerbation of Sweet's syndrome, but showed some decrease during isotretinoin therapy. Other functions, such as phagocytosis, metabolic activation, and bacterial killing, also were slightly increased. In addition, the patient's serum contained a heat-stable, nonlipid chemoattractant that was present at all times except during a course of isotretinoin. Although his symptoms responded to aspirin, the plasma continued to show this chemoattractant. These findings are consistent with the hypothesis that excess chemoattractant in Sweet's syndrome attracts neutrophils, which then mediate an inflammatory response. In addition, aspirin may be used to control Sweet's syndrome symptoms, although it does not suppress the plasma chemoattractant.
D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D002634:Chemotaxis, Leukocyte; D003956:Dialysis; D006358:Hot Temperature; D006801:Humans; D015474:Isotretinoin; D007964:Leukocytosis / Q000097:blood* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D008297:Male; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000097:blood; D009504:Neutrophils / Q000276:immunology / Q000502:physiology*; D010427:Pentose Phosphate Pathway; D010587:Phagocytosis; D010949:Plasma / Q000187:drug effects; D012871:Skin Diseases / Q000097:blood* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D013577:Syndrome; D014212:Tretinoin / Q000627:therapeutic use; D015054:Zymosan / Q000494:pharmacology
D014212:Tretinoin; D009240:N-Formylmethionine Leucyl-Phenylalanine; D015054:Zymosan; D015474:Isotretinoin; D001241:Aspirin